Lisata Therapeutics Inc./$LSTA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
- Ticker
- $LSTA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 21
- Headquarters
- Basking Ridge, United States
- Website
- www.lisata.com
LSTA Metrics
BasicAdvanced
$11M
-
-$1.64
0.94
-
Price and volume
Market cap
$11M
Beta
0.94
52-week high
$5.07
52-week low
$0.96
Average daily volume
131K
Financial strength
Current ratio
3.687
Quick ratio
3.563
Profitability
EBITDA (TTM)
-16.362
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-14,621.00%
Operating margin (TTM)
-16,426.00%
Effective tax rate (TTM)
2.58%
Management effectiveness
Return on assets (TTM)
-56.74%
Return on equity (TTM)
-101.66%
Valuation
Price to revenue (TTM)
106.961
Price to book
1.33
Price to tangible book (TTM)
1.33
Price to free cash flow (TTM)
-0.868
Free cash flow yield (TTM)
-115.22%
Free cash flow per share (TTM)
-1.383
Growth
Revenue change (TTM)
-90.65%
Earnings per share change (TTM)
-26.48%
10-year revenue growth (CAGR)
-38.75%
3-year earnings per share growth (CAGR)
-39.70%
10-year earnings per share growth (CAGR)
-37.09%
LSTA Financial Performance
Revenues and expenses
LSTA Earnings Performance
Company profitability
Upcoming events
No upcoming events
LSTA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.